The need-to-know this morning includes Amylyx Pharmaceuticals removing its ALS treatment from the market after it failed to show benefits in a clinical trial. A study suggests a GLP-1 drug could be effective in treating Parkinson’s disease. BIO’s CEO emphasizes the importance of the U.S. maintaining its leadership in biotechnology for national security reasons. Resurrecting extinct species like mammoths could impact medicine by providing insights into genetics. Moderna is working on mRNA treatments for rare diseases like propionic acidemia. Additionally, other news includes a drugmaker seeking approval for China’s first biosimilar and FDA approving Basilea Pharmaceuticals’ antibiotic.
Source link
Readout Newsletter: Amylyx, Parkinson’s, Moderna updates
